Allon Therapeutics I (NPCUF) 0.0005 $NPCUF Canfor

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Allon Therapeutics I (NPCUF) 0.0005 $NPCUF

Canfor Corporation and Canfor Pulp Products Inc. Announce Fourth Quarter Results Conference Call
Marketwire - Wed Jan 15, 5:19PM CST
Canfor Corporation (TSX: CFP) and Canfor Pulp Products Inc. (TSX: CFX) will hold a joint conference call on Thursday, February 6, 2014 at 8:00 AM PST to discuss their respective fourth quarter 2013 financial and operating results. To participate in the call, please dial one of the following numbers:

Merchants Bancshares IncCorporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 7:59PM CST
Trading resumes in:

MB Financial Inc.Corporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 7:59PM CST
Trading resumes in:

Lindsay CorporationCorporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 7:58PM CST
Allon Therapeutics Inc. (TSX: NPC) announced today that its pivotal clinical trial evaluating its lead product candidate davunetide as a treatment for progressive supranuclear palsy (PSP) failed to demonstrate efficacy in this population.

Lockheed Martin CorporationCorporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 7:58PM CST
The following issues have been halted by IIROC:

American Securities Completes Acquisition of Frontier Spinning Mills
PR Newswire - Thu Dec 19, 11:00AM CST
American Securities LLC, a leading U.S. private equity firm, today announced that, in partnership with management, it has completed the acquisition of Frontier Spinning Mills Holding Corp., a leading producer of cotton yarn for the knitting and weaving industries, from an affiliate of Sun Capital Partners, Inc. Financial terms of the transaction were not disclosed.

Anavex Appoints Alzheimer's Industry Leader to Scientific Advisory Board
PR Newswire - Tue Dec 03, 6:30AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB: AVXL) today announced the appointment of Michael Gold, MD, as a member of its Scientific Advisory Board. Dr. Gold has over 20 years of experience in the clinical development of Alzheimer's and other central nervous system (CNS) drugs and currently serves as Vice President of the CNS practice at UCB, Inc., a global biopharmaceutical company. His background also includes leadership roles with GlaxoSmithKline (GSK), Johnson & Johnson (J&J) and Bristol-Myers Squibb (BMS).

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2012
M2 - Fri Aug 02, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/93dth7/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for peripheral neuropathy (sensory neuropathy), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for peripheral neuropathy (sensory neuropathy). The information is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for peripheral neuropathy (sensory neuropathy). - A review of the peripheral neuropathy (sensory neuropathy) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the peripheral neuropathy (sensory neuropathy) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Peripheral Neuropathy (Sensory Neuropathy) Overview Therapeutics Development An Overview of Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) Companies Involved in Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Development Drug Profiles Featured News & Press Releases Appendix Companies Mentioned - Allon Therapeutics Inc - Neuren Pharmaceuticals Limited - NeurogesX, Inc - NsGene A/S For more information visit http://www.researchandmarkets.com/research/93dth7/peripheral

Paladin Labs Inc. Acquires Allon Therapeutics Inc.
Marketwire - Tue Jul 16, 3:31PM CDT
Paladin Labs Inc. (TSX: PLB) ("Paladin" and/or the "Company"), a leading Canadian specialty pharmaceutical company, and Allon Therapeutics Inc. (TSX: NPC) announced today that in accordance with the Order for Reorganization in Allon's proposal proceedings under the Bankruptcy and Insolvency Act (Canada) and under the Canada Business Corporations Act which have been previously announced, Paladin has become the sole shareholder of Allon.

IIROC Trade Halt - Allon Therapeutics Inc.
Newsfile Corp - Thu May 30, 7:23AM CDT
The following issues have been halted by IIROC:

Cognitive Impairment - Pipeline Review, H1 2013
M2 - Tue Apr 23, 5:08AM CDT
Research and Markets has announced the addition of the Cognitive Impairment - Pipeline Review, H1 2013 report to their offering. 'Cognitive Impairment - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cognitive Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cognitive Impairment. Scope - A snapshot of the global therapeutic scenario for Cognitive Impairment. - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cognitive Impairment pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Cognitive Impairment Therapeutics Development - Albany Molecular Research, Inc. - Allon Therapeutics Inc. - Amgen Inc. - AstraZeneca PLC - Avineuro Pharmaceuticals, Inc. - BIOPROJET SCR - Bio-Link - Bionomics Limited - Boehringer Ingelheim GmbH - Celon Pharma Sp. z o.o. - Chiesi Farmaceutici SpA - Dart NeuroScience LLC - Eli Lilly and Company - Envoy Therapeutics, Inc. - Evotec Aktiengesellschaft - Galenea Corp. - GlaxoSmithKline plc - Heptares Therapeutics Ltd. - Merck & Co., Inc. - Mithridion, Inc. - Omeros Corporation - Pfizer Inc. - Pherin Pharmaceuticals, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - SeneXta Therapeutics SA - Suven Life Sciences Ltd. - Takeda Pharmaceutical Company Limited - Theratechnologies Inc. For more information visit Cognitive Impairment - Pipeline Review, H1 2013

Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2013 Reviews Key Players Involved In the Therapeutic Development for Amyotrophic Lateral Sclerosis
M2 - Fri Apr 12, 11:28AM CDT
Research and Markets has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Amyotrophic

Allon provides shareholder update
CNW Group - Tue Feb 05, 5:00PM CST
Allon Therapeutics Inc. (TSX: NPC) announced today that its previously announced strategic review has generated a number of different strategic alternatives and opportunities that are being actively evaluated. The Company is aggressively managing ongoing operating expenses. This strategic review process includes considering all reasonable options for exploiting Allon's assets as well as securing additional financing.

TSX Delisting Review - Allon Therapeutics Inc. (Symbol: NPC)
CNW Group - Tue Feb 05, 7:45AM CST
DELISTING REVIEW Allon Therapeutics Inc. (the "Company") - TSX is reviewing the Common Shares (Symbol: NPC) of the Company with respect to meeting the continued listing requirements. The Company has been granted 120 days in which to regain compliance with these requirements, pursuant to the Remedial Review Process.

Allon director takes new role
CNW Group - Wed Jan 30, 4:30PM CST
Allon Therapeutics Inc. (TSX: NPC) announced today that Mr. Michael Aldridge, Director of the Company since June 2011, has resigned to accept a new professional responsibility in the biotech industry.

Dementia - Pipeline Review, H2 2012: Plan Mergers and Acquisitions Effectively By Identifying Players of the Most Promising Pipeline
M2 - Mon Jan 14, 10:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/jbsd8v/dementia) has announced the addition of Global Markets Direct's new report "Dementia - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Dementia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dementia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dementia. Dementia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Dementia. - Coverage of products

Allon cuts staff and administrative costs
CNW Group - Fri Dec 21, 3:00PM CST
Allon Therapeutics Inc. (TSX: NPC) announced today that, after the negative results in its pivotal davunetide study, it has implemented staff and administrative reductions.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 31

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 61

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 48

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 35

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 44

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Kinross Gold Faces Class Action Over Misleading Forecasts

Updated Category News Views 51

A Golden Opportunity Gone Wrong Well, it looks like Kinross Gold Corporation (NYSE: KGC) has stuck its foot in it again. This time, they're in hot water over claims that don't exactly hold up under scrutiny. If you're holding KGC, you've probably heard about the fresh class action lawsuit alleging they misled investors about their production targets. Naturally, the...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 71

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 55

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 139

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 124

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading

Top 5 Most Recently Viewed Articles

Cytek Biosciences Prepares for Q2 2025 Financial Results Report

Updated Category News Views 214

Cytek Biosciences Plans Financial Disclosure for Second Quarter 2025 Cytek Biosciences, Inc. (NASDAQ: CTKB), based in Fremont, California, has dynamic news for stakeholders. The company is set to disclose its financial results for the second quarter of 2025 on August 6, 2025. This critical deadline follows the market closure that day, allowing for a comprehensive analysis...

Continue Reading
Alliance Trust PLC Shares Up: Latest NAV Per Share Insights

Updated Category News Views 171

Alliance Trust PLC Alliance Trust PLC's recent trading data dropped some key numbers that had traders buzzing. The Net Asset Value (NAV) per ordinary share hit the screens, giving everyone a fresh angle on how the company was really performing in a choppy market. NAV Breakdown: What's It Telling Us? Here's how the NAV shook out on the latest report: Valued on a Bid Price...

Continue Reading
Man Group Investment Insights: Spirent Communications and Trends

Updated Category News Views 199

Investment Insights from Man Group regarding Spirent Communications In today’s evolving market, understanding the dynamics between significant firms like Man Group PLC and Spirent Communications plc is vital for investors. This disclosure provides a snapshot of Man Group’s holdings and interests, particularly in relation to investing more than 1% in relevant...

Continue Reading
Sunny Lowe Joins Prime Mining Corp's Board of Directors

Updated Category News Views 221

Prime Mining Corp. (TSX: PRYM) (Other OTC: PRMNF) (Frankfurt: O4V3) has recently appointed Sunny Lowe to its Board of Directors. This announcement highlights a strategic move by the company to strengthen its leadership team as it continues its key projects, particularly the Los Reyes Project. Welcome to Sunny Lowe Murray John, Chair of the Board, expressed enthusiasm...

Continue Reading
Spotlight on Magnificent 7 Stocks: Opportunities in a Turbulent Market

Updated Category News Views 190

Market Overview: Understanding the Current Landscape The technology sector has seen major fluctuations recently, prompting discussions about the best investment opportunities. Economic uncertainties and market instability have resulted in significant stock losses, making this a pivotal moment for investors. The backdrop of Trump’s trade policies adds another layer of...

Continue Reading